| Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry. | |
| | |
MedLine Citation:
|
PMID: 19056134 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The long-term safety and efficacy of drug eluting stents (DES) implanted during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is unclear. The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES vs. bare metal stent (BMS) implantation. METHODS: In the present analysis 4764 patients were enrolled (706, 15%, received DES). We assessed the cumulative incidence of major adverse cardiac events (MACE) and stent thrombosis (ST). RESULTS: Overall, no significant difference emerged for the rates of death and reinfarction. DES implantation was associated to a reduction of target vessel revascularization (TVR) (HR 0.65, 95%CI 0.47-0.91; p=0.01), leading to a MACE reduction (HR 0.7, 95%CI 0.56-0.86; p<0.01). In particular, during the first 2 years we observed less adverse events in the DES group, mainly because of a lower TVR rate (TVR: HR 0.56, 95%CI 0.37-0.83, p<0.01; MACE: HR 0.71, 95%CI 0.54-0.94, p=0.01). On the contrary, during the third year, adverse events tended to be higher in the DES group. ST did not differ between DES and BMS groups (p=0.6). No differences were observed between sirolimus eluting stents and paclitaxel eluting stents. CONCLUSIONS: DES implantation during primary PCI is safe and associated with a significant TVR and MACE reduction in the first two years, whereas a trend to have more adverse events in the third year is observed. More data about long-term follow-up are needed to better evaluate both safety and efficacy of DES in the setting of STEMI. |
| | |
Authors:
|
Gianluca Campo; Francesco Saia; Gianfranco Percoco; Antonio Manari; Andrea Santarelli; Luigi Vignali; Elisabetta Varani; Alberto Benassi; Pietro Sangiorgio; Fabio Tarantino; Paolo Magnavacchi; Rossana De Palma; Paolo Guastaroba; Antonio Marzocchi |
Related Documents
:
|
11078244 - Ten-year clinical and angiographic follow-up of coronary wallstent. 1797224 - Effect of a metallic balloon-expanded stent on normal rabbit ureter. 12840244 - The first clinical experience with a peripheral, self-expanding nitinol stent in the tr... 19309734 - Neointimal regression-induced incomplete coverage of a bare-metal stent in the left mai... 15084544 - Pulsed wave tissue doppler imaging for the quantification of contractile reserve in stu... 9746484 - Overexpression of alpha1b-adrenergic receptor induces left ventricular dysfunction in t... |
Publication Detail:
|
Type: Journal Article Date: 2008-12-03 |
Journal Detail:
|
Title: International journal of cardiology Volume: 140 ISSN: 1874-1754 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-04-12 Completed Date: 2010-07-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 154-60 Citation Subset: IM |
Copyright Information:
|
Copyright 2008 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Unità Operativa di Cardiologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy. cmpglc@unife.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Transluminal, Percutaneous Coronary* Antineoplastic Agents, Phytogenic / therapeutic use Coronary Restenosis / epidemiology* Coronary Thrombosis / epidemiology* Drug-Eluting Stents / adverse effects, statistics & numerical data* Electrocardiography Female Follow-Up Studies Humans Immunosuppressive Agents / therapeutic use Incidence Male Middle Aged Myocardial Infarction / diagnosis, epidemiology*, therapy* Paclitaxel / therapeutic use Registries / statistics & numerical data Sirolimus / therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Phytogenic; 0/Immunosuppressive Agents; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High net calcium uptake explains the hypersensitivity of the freshwater pulmonate snail, Lymnaea sta...
Next Document: Instent neointimal hyperplasia after percutaneous intervention for ST-elevation myocardial infarctio...